Experimental strategies to reverse chronic renal disease - PubMed

Affiliations

• PMID: 15359103
• DOI: 10.1159/000080790

Review

Experimental strategies to reverse chronic renal disease

Michael Zeisberg et al. Blood Purif. 2004.

Abstract

Progression of chronic nephropathies still represents a major challenge for clinical nephrologists. Specific therapies that prevent patients from requiring dialysis or transplantation are still not available. However, recent experimental studies have demonstrated that regression of advanced lesions in the kidney can be achieved. This review summarizes the recent therapeutic advances using experimental models that might translate into novel human therapies to prevent, or significantly delay, requirement of renal replacement therapy.

Similar articles

• Progression of chronic kidney disease: can it be prevented or arrested?

  Jaber BL, Madias NE. Jaber BL, et al. Am J Med. 2005 Dec;118(12):1323-30. doi: 10.1016/j.amjmed.2005.02.032. Am J Med. 2005. PMID: 16378772 Review.

• Effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with chronic kidney disease.

  Kolesnyk I, Struijk DG, Dekker FW, Krediet RT. Kolesnyk I, et al. Neth J Med. 2010 Jan;68(1):15-23. Neth J Med. 2010. PMID: 20103817 Review.

• The Remission Clinic approach to halt the progression of kidney disease.

  Remission Clinic Task Force; Clinical Research Center "Aldo e Cele Daccò". Remission Clinic Task Force, et al. J Nephrol. 2011 May-Jun;24(3):274-81. doi: 10.5301/JN.2011.7763. J Nephrol. 2011. PMID: 21534237

Cited by

• Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition.

  Zeisberg EM, Potenta SE, Sugimoto H, Zeisberg M, Kalluri R. Zeisberg EM, et al. J Am Soc Nephrol. 2008 Dec;19(12):2282-7. doi: 10.1681/ASN.2008050513. Epub 2008 Nov 5. J Am Soc Nephrol. 2008. PMID: 18987304 Free PMC article.

• Thrombospondin-1 deficiency causes a shift from fibroproliferative to inflammatory kidney disease and delays onset of renal failure.

  Zeisberg M, Tampe B, LeBleu V, Tampe D, Zeisberg EM, Kalluri R. Zeisberg M, et al. Am J Pathol. 2014 Oct;184(10):2687-98. doi: 10.1016/j.ajpath.2014.06.014. Epub 2014 Aug 10. Am J Pathol. 2014. PMID: 25111226 Free PMC article.

• Lin28a attenuates TGF-β-induced renal fibrosis.

  Jung GS, Hwang YJ, Choi JH, Lee KM. Jung GS, et al. BMB Rep. 2020 Nov;53(11):594-599. doi: 10.5483/BMBRep.2020.53.11.153. BMB Rep. 2020. PMID: 33050985 Free PMC article.

• Invariant natural killer T cell agonist modulates experimental focal and segmental glomerulosclerosis.

  Pereira RL, Reis VO, Semedo P, Buscariollo BN, Donizetti-Oliveira C, Cenedeze MA, Soares MF, Pacheco-Silva A, Savage PB, Câmara NO, Keller AC. Pereira RL, et al. PLoS One. 2012;7(3):e32454. doi: 10.1371/journal.pone.0032454. Epub 2012 Mar 12. PLoS One. 2012. PMID: 22427838 Free PMC article.

• Cellular mechanisms of tissue fibrosis. 1. Common and organ-specific mechanisms associated with tissue fibrosis.

  Zeisberg M, Kalluri R. Zeisberg M, et al. Am J Physiol Cell Physiol. 2013 Feb 1;304(3):C216-25. doi: 10.1152/ajpcell.00328.2012. Epub 2012 Dec 19. Am J Physiol Cell Physiol. 2013. PMID: 23255577 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • S. Karger AG, Basel, Switzerland

• Medical

  • MedlinePlus Health Information